{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:48:39Z","timestamp":1784764119016,"version":"3.55.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Kimura disease (KD) is a rare, chronic angiolymphoproliferative inflammatory disease appearing to be mostly restricted to the skin and soft tissue. Cutaneous involvement of KD includes head and\/or neck nodules showing suggestive histological features, frequently associated with an atopic dermatitis-like or prurigo-like presentation. KD is challenging to treat, with high rate of recurrence using current therapeutic strategies. Evidence for involvement of a T-helper type 2 (Th2) immune response in KD pathogenesis has been found in previous studies. Consequently, this study aimed to determine the efficacy and safety of dupilumab, a human monoclonal antibody that inhibits signalling of key Th2 cytokines, interleukin (IL)-4 and IL-13, within a single-centre cohort of patients with cutaneous KD. Two adults with a diagnosis of refractory (failure of at least one treatment line) cutaneous-restricted KD based on clinical, biological, histological, molecular and imaging findings received dupilumab for KD, and showed dramatic response with a good safety profile.<\/jats:p>","DOI":"10.1093\/ced\/llad455","type":"journal-article","created":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T15:28:59Z","timestamp":1703431739000},"page":"502-506","source":"Crossref","is-referenced-by-count":8,"title":["Two cases of dupilumab-responsive Kimura disease"],"prefix":"10.1093","volume":"49","author":[{"given":"Gilles","family":"Battesti","sequence":"first","affiliation":[{"name":"Departments of Dermatology"},{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Jachiet","sequence":"additional","affiliation":[{"name":"Departments of Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Lepelletier","sequence":"additional","affiliation":[{"name":"Departments of Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Petit","sequence":"additional","affiliation":[{"name":"Departments of Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Dominique","family":"Vignon-Pennamen","sequence":"additional","affiliation":[{"name":"Pathology, Saint-Louis Hospital , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Cassius","sequence":"additional","affiliation":[{"name":"Departments of Dermatology"},{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e8le","family":"de Masson","sequence":"additional","affiliation":[{"name":"Departments of Dermatology"},{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Battistella","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris , France"},{"name":"Pathology, Saint-Louis Hospital , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[{"name":"Departments of Dermatology"},{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean David","family":"Bouaziz","sequence":"additional","affiliation":[{"name":"Departments of Dermatology"},{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Mah\u00e9vas","sequence":"additional","affiliation":[{"name":"Departments of Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,27]]},"reference":[{"key":"2024042613110666600_llad455-B1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000439346","article-title":"Retrospective multicentric study of 25 Kimura disease patients: emphasis on therapeutics and shared features with cutaneous IgG4-related disease","volume":"231","author":"Kottler","year":"2015","journal-title":"Dermatology"},{"key":"2024042613110666600_llad455-B2","first-page":"21414","article-title":"Kimura\u2019s disease: risk factors of recurrence and prognosis","volume":"8","author":"Chen","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"2024042613110666600_llad455-B3","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1365-2133.1997.tb01562.x","article-title":"In vivo expression of IL-4, IL-5, IL-13 and IFN-\u03b3 mRNAs in peripheral blood mononuclear cells and effect of cyclosporin A in a patient with Kimura\u2019s disease","volume":"137","author":"Katagiri","year":"1997","journal-title":"Br J Dermatol"},{"key":"2024042613110666600_llad455-B4","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.humimm.2013.06.001","article-title":"Increased CD45RO+ CD62L+ CD4+ T-cell subpopulation responsible for Th2 response in Kimura\u2019s disease","volume":"74","author":"Yamazaki","year":"2013","journal-title":"Hum Immunol"},{"key":"2024042613110666600_llad455-B5","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1016\/j.jaip.2021.02.049","article-title":"Mepolizumab-responsive Kimura disease","volume":"9","author":"Kinoshita","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024042613110666600_llad455-B6","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.42043","article-title":"CD163+ M2 macrophages promote fibrosis in IgG4-related disease via Toll-like receptor 7 interleukin-1 receptor-associated kinase 4\/NF-\u03baB signaling","volume":"74","author":"Chinju","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2024042613110666600_llad455-B7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/00313028409067909","article-title":"Kimura\u2019s disease: a clinico-pathological study of 21 cases and its distinction from angiolymphoid hyperplasia with eosinophilia","volume":"16","author":"Kung","year":"1984","journal-title":"Pathology"},{"key":"2024042613110666600_llad455-B8","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"key":"2024042613110666600_llad455-B9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/jamadermatol.2021.5885","article-title":"Treatment of Kimura disease with dupilumab","volume":"158","author":"Teraki","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2024042613110666600_llad455-B10","doi-asserted-by":"crossref","first-page":"1084879","DOI":"10.3389\/fimmu.2022.1084879","article-title":"Successful treatment of dupilumab in Kimura disease independent of IgE: a case report with literature review","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llad455\/56879529\/llad455.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/5\/502\/57339256\/llad455.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/5\/502\/57339256\/llad455.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T13:11:19Z","timestamp":1714137079000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/5\/502\/7499795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":10,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,12,27]]},"published-print":{"date-parts":[[2024,4,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llad455","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2023,12,27]]}}}